2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-184177
    W2A-28 2803203-72-5
    W2A-28 is a daul modulator of class I HDACs and Wnt/β-catenin. W2A-28 inhibits HDAC1, 2 and 3 activities with IC50 values of 512, 675, and 217 nM, respectively. W2A-28 shows selectivity over other HDACs and Sirtuin family members. W2A-28 activates Wnt/β-catenin signaling via reduced LRP6 degradation, enhances histone acetylation, suppresses tau phosphorylation, and reduces Aβ40 and Aβ42 levels. W2A-28 can be used for the research of Alzheimer's disease.
    W2A-28
  • HY-184183
    MT5-MMP-IN-1
    MT5-MMP-IN-1 is a non-peptidic MT5-MMP (MMP-24) inhibitor with an IC50 of 6 μM. MT5-MMP-IN-1 interacts with the catalytic zinc ion of MT5-MMP via a hydroxamic acid zinc-binding group. MT5-MMP-IN-1 is applicable to the research of Alzheimer's disease.
    MT5-MMP-IN-1
  • HY-184192
    R-185 3066783-67-0 98%
    R-185 is an orally active and brain-penetrant GPR52 agonist. R-185 activates GPR52 to increase intracellular cAMP levels. R-185 can be used for the research of schizophrenia.
    R-185
  • HY-184198
    LRRK2-IN-22 1427947-55-4
    LRRK2-IN-22 is a LRRK2 inhibitor, with IC50 values of 315.7 nM and 255.4 nM against LRRK2WT and LRRK2G2019S, respectively. LRRK2-IN-22 effectively inhibits LRRK2 kinase activity and downstream Rab10 phosphorylation, reduces ROS, and exhibits low cytotoxicity. LRRK2-IN-22 can be used for research on Parkinson's disease.
    LRRK2-IN-22
  • HY-184206
    A-3190
    A-3190 is an orally active, blood-brain barrier permeable CD38 inhibitor, with an IC50 of 7.25 nM against human CD38 and 1.24 nM against mouse CD38. A-3190 is a derivative of A-8531 (HY-184021), and it forms covalent adducts with NAD+ in the presence of CD38. A-3190 acts as an inducer of NAD+ levels and an inhibitor of NAM and ADPR levels. A-3190 increases NAD+ levels in the skin, lung, liver and brain of rodents, while reducing NAM and ADPR levels in brain tissues. A-3190 can be used in research related to multiple sclerosis, Parkinson's disease and Alzheimer's disease.
    A-3190
  • HY-184207
    Zinc13732787 119486-83-8
    Zinc13732787 is an inhibitor of the KCNQ1/KCNE1 potassium channel complex, with no activity against the KCNQ2/KCNQ3 channel. Zinc13732787 reduces axonal growth in human neural stem cells, while exerting no effect on KCNQ1-knockout neural stem cells. Zinc13732787 can be used for research on arrhythmia, epilepsy, and neuropsychiatric disorders.
    Zinc13732787
  • HY-184208
    MCL-524 1863967-01-4
    MCL-524 is a highly selective full agonist of the dopamine D2 receptor with a Kd value of 1.34 nM. MCL-524 specifically binds to the high-affinity state of the dopamine D2 receptor; this binding is abolished by guanylylimidodiphosphate, and it can distinguish between D2high and D2low sites. MCL-524 is applicable to research related to Parkinson's disease and schizophrenia.
    MCL-524
  • HY-184246
    SR-34831 2791469-19-5 98%
    SR-34831 is a NAMPT activator, NAD level stabilizer and neuroprotective agent. SR-34831 enhances the enzymatic activity of human NAMPT, prevents intracellular NAD depletion, and counteracts neuronal death induced by toxic misfolded prion proteins. SR-34831 exhibits metabolic stability in human liver microsomes and can be used for the research of protein misfolding neurodegenerative diseases.
    SR-34831
  • HY-184247
    SR-32685 2791469-14-0
    SR-32685 is a NAMPT activator and neuroprotective agent. SR-32685 enhances the enzymatic activity of hNAMPT, prevents intracellular NAD depletion, and protects neurons from death induced by toxic misfolded prion proteins. SR-32685 can be used in the research of protein misfolding neurodegenerative diseases and metabolic diseases.
    SR-32685
  • HY-184480
    PROTAC HTT Degrader-1 2133321-59-0
    PROTAC HTT Degrader-1 is a cIAP1-recruiting Htt PROTAC degrader. PROTAC HTT Degrader-1 recruits cIAP1 to mHtt or wtHtt and induces their degradation via the ubiquitin-proteasome system. PROTAC HTT Degrader-1 can be used in research related to Huntington's disease.
    PROTAC HTT Degrader-1
  • HY-184481
    DHPT-PEG2-C2-NH2 2133002-45-4
    DHPT-PEG2-C2-NH2 (Compound 15) is a Target Protein Ligand-Linker Conjugate that contains an Htt ligand (HY-W040269) and a PROTAC linker (HY-W007545), and can recruit E3 ligases. JQ-1-Azidopropylamine is applicable for the synthesis of PROTAC HTT Degrader-1 (HY-184480).
    DHPT-PEG2-C2-NH2
  • HY-185007
    LI-633 1849624-82-3
    LI-633 is a selective and orally active GABAA receptor positive allosteric modulator (PAM) with a Ki of 21 nM. LI-633 produces robust potentiation of GABA-induced inward current, with EC50 values ranging from 8 nM (α5β2γ2) to 128 nM (α3β2γ2). LI-633 potentiates muscimol-induced GABAergic currents in rat dorsal root ganglion (DRG) neurons with an EC50 of 70.4 nM. LI-633 can be used for the study of visceral pain.
    LI-633
  • HY-185027
    Memagal 1402938-19-5
    Memagal is an AchE inhibitor (IC50 = 1.16 nM) and a NMDAR antagonist (Ki = 4.6 μM). Memagal inhibits the neurotoxicity induced by NMDA (HY-17551), with its IC50 value being 0.28 nM. Memagal can be used for research on Alzheimer's disease.
    Memagal
  • HY-185056
    Ferfluor-1 3030473-59-4 99.33%
    Ferfluor-1 is a Ferroptosis inhibitor (EC50 of 57 nM in HT108 cells; EC50 of 75 nM in OS-RC-2 cells; EC50 of 2.3 nM in SH-SY5Y neuroblastoma cells), and ratiometric photoluminescent probe with blood-brain barrier permeability. Ferfluor-1 is a specific indicator for the fluctuation of Ferroptosis. Ferfluor-1 alleviates brain disorder diseases of in vivo stroke and PD models.
    Ferfluor-1
  • HY-185141
    IP6K-IN-2 3024590-83-5
    IP6K-IN-2 is an inositol hexakisphosphate kinase (IP6K1) inhibitor that inhibits IP6K1 enzyme activity with an IC50 value of 110 nM. IP6K-IN-2 can be used for the research of neurological disease and CNS disorders.
    IP6K-IN-2
  • HY-185187
    AAK1-IN-12 2892117-23-4
    AAK1-IN-12 (Compound 4) is a selective, orally active AAK1 inhibitor that can cross the blood-brain barrier. AAK1-IN-12 is applicable to the research of schizophrenia, Parkinson's disease, neuropathic pain and Alzheimer's disease.
    AAK1-IN-12
  • HY-185311
    NEK7 degrader-3 3119435-52-5 98%
    NEK7 degrader-3 is an orally active and brain-penetrant NEK7 molecular glue degrader with a DC50 of 33.1 nM. NEK7 degrader-3 mediates interaction between NEK7 and E3 ligase cereblon, promoting proteasomal degradation of NEK7 and attenuating NLRP3 inflammasome-mediated inflammatory responses. NEK7 degrader-3 inhibits caspase-1 activity, cytokine release of IL-1β, IL-1α, and IL-18, and pyroptosis-related plasma membrane permeabilization. NEK7 degrader-3 shows antiinflammatory activity in an LPS (HY-D1056)-induced neuroinflammation mouse model. NEK7 degrader-3 can be used for the research of neuroinflammation.
    NEK7 degrader-3
  • HY-185333
    Sodium Channel-IN-7 2914907-77-8
    Sodium Channel-IN-7 (Example 59) is a NaV1.7 voltage-gated sodium channel inhibitor.Sodium Channel-IN-7 binds to the VSD4 binding pocket of NaV1.7, with reduced interaction with Try1537.Sodium Channel-IN-7 can be used for the research of pain.
    Sodium Channel-IN-7
  • HY-185346
    AChE-IN-113 2365416-33-5
    AChE-IN-113 is a selective acetylcholinesterase inhibitor with a Ki value of 8.3 μM against electric eel acetylcholinesterase. AChE-IN-113 can be used for the research of Alzheimer's disease.
    AChE-IN-113
  • HY-185347
    AChE-IN-114 2365405-51-0 98%
    AChE-IN-114 is a selective AChE inhibitor and shows weak inhibitory activity for BChE. AChE-IN-114 can be used for the research of alzheimer’s disease.
    AChE-IN-114
Cat. No. Product Name / Synonyms Application Reactivity